Supplementary Tables and Figures from IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis

Table S1: Clinicopathological features of LAC patients and control LAC-free individuals. Table S2: Primers used in qPCR assays. Figure S1: Augmented Kras-induced lung adenocarcinoma in gp130F/F mice is not associated with enhanced inflammation. Figure S2: Gene expression analyses during KrasG12D-induced lung carcinogenesis. Figure S3: IL-6 deficiency in the lungs of gp130F/F:KrasG12D mice suppresses cellular apoptosis and inflammation. Figure S4: Nuclear expression of tyrosine-phosphorylated (activated) STAT3 in the epithelial lesions in the lungs of F/F:KrasG12D mice. Figure S5: Reduced STAT3 activation in the lungs of gp130F/F mice upon genetic ablation of IL-6 trans-signaling with sgp130Fc. Figure S6: Blockade of IL-6 trans-signaling with mAbs in KrasG12D mice reduces lung carcinogenesis. Figure S7: Blockade of IL-6 trans-signaling suppresses the growth of human LAC cell lines.